Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

Outlook Therapeutics, Inc.’s OTLK share price has dipped by 6.40%, which has investors questioning if this is right time to ...

Dr. Davide Soldato (Host), Dr. Harriet Kluger (Guest) Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...